Naduparambil Jacob PhD

Naduparambil Jacob PhD
Asst ProfessorCollege of
351 Wiseman Hall 400 W 12th Avenue Columbus Ohio 43210
Phone:614-685-4246Fax: (614) 366-1938
  • Translational Therapeutics

General Research Interest

Targeting mitotic machinery (Aurora B kinase and Survivin) in cancers, DNA double strand break repair, Radiation Biodosimetry, Radio-protectors and Radio-sensitizers.

Research Description

My research focus/areas of interests include: a) Biomarkers for early prediction of the delayed effects of normal tissue injury following radiation disaster or therapeutic exposure: The ultimate goal is to develop non-invasive serum/urine based biodosimetry and therapeutic strategies for timely intervention prior to expression of the disease. b) Mechanisms of therapeutic resistance in malignant brain tumors: We are interested in the epigenetic modulators which define the competence of chromatin in DNA repair and understanding how it varies in normal tissue, radiation sensitive and resistant tumor tissues, with emphasis on GBM. The ultimate goal is to develop novel/ improved strategies for radio-sensitization of cancer cells, protecting normal cells and thereby achieving better therapeutic ratio. c) Targeting the mitotic machinery in cancers: In collaboration with investigators at OSU College of Pharmacy, we have developed and tested several novel small molecules that inhibit survivin function in the Chromosomal Passenger Complex (CPC) and its association with Aurora-B kinase, another critical regulator of mitotic progression. We are currently investigating the efficacy of these agents. d) Investigate the therapeutic, radio-protective and radio-sensitizing effects of selected natural products in mouse models.

Current Publications

  • Wojton J, Meisen WH, Jacob NK, Thorne AH, Hardcastle J, Denton N, Chu Z, Dmitrieva N, Marsh R, Van Meir EG, Kwon CH, Chakravarti A, Qi X, Kaur BSapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma.Oncotarget in press 7/17/2014
  • Palmieri D, Costinean S, Shapiro CL, Huebner K, Croce CM, Gasparini P, Lovat F, Fassan M, Casadei L, Cascione L, Jacob NK, Carasi SProtective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation.Proc Natl Acad Sci U S A 111 4536-41 3/25/2014
  • Martin LK, Cordero-Nieves HM, Banasavadi-Siddegowda Y, Virk S, Barnholtz-Sloan J, Bell EH, Wojton J, Jacob NK, Chakravarti A, Nowicki MO, Wu X, Lapalombella R, Datta J, Yu B, Gordon K, Haseley A, Patton JT, Smith PL, Ryu J, Zhang X, Yan F, Alinari L, Lustberg ME, Mo X, Marcucci G, Nuovo G, Kwon CH, Byrd JC, Chiocca EA, Li C, Sif S, Jacob S, Lawler S, Kaur B, Baiocchi RAGenetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.Cancer Res 74 1752-65 3/15/2014
  • Harshman SW, Chen MM, Branson OE, Jacob NK, Johnson AJ, Byrd JC, Freitas MAIsolation and analysis of linker histones across cellular compartments.J Proteomics 91 595-604 10/8/2013
  • Chettiar SN, Cooley JV, Park IH, Bhasin D, Chakravarti A, Li PK, Li C, Jacob NKDesign, synthesis and biological studies of survivin dimerization modulators that prolong mitotic cycle.Bioorg Med Chem Lett 23 5429-33 10/1/2013
  • Jacob NK, Lapalombella R, McGourty J, Rafiq S, Siadak A, Butchar JP, Cheney C, Lozanski G, Moledor M, Lowe R, Setter B, Jones J, Flynn JM, Andritsos L, Devine S, Mo X, Jarjoura D, Tridandapani S, Algate P, Byrd JC, Muthusamy NGlycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.MAbs 5 723-35 9/1/2013
  • Jacob NK, Cooley JV, Yee TN, Jacob J, Alder H, Wickramasinghe P, Maclean KH, Chakravarti AIdentification of sensitive serum microRNA biomarkers for radiation biodosimetry.PLoS One 8 e57603 1/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: